Question 1

Has Kerem Ozer received payments from drug or device companies?

Accepted Answer

Yes. Drug and device makers reported $2,266,129 in general payments to Kerem Ozer across 1,165 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Question 2

Does a payment mean Kerem Ozer did something wrong?

Accepted Answer

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Question 3

Where does this information about Kerem Ozer come from?

Accepted Answer

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Company	Payments	Total
Eli Lilly	21	$758,835
Abbott	61	$383,930
AbbVie(2 entities)	88	$329,758
Medtronic(2 entities)	31	$299,577
Lilly USA, LLC	355	$139,275
Novo Nordisk AS	422	$106,402
Senseonics, Incorporated	43	$92,518
BD	2	$49,038
Novo Nordisk	58	$38,345
Dexcom, Inc.	3	$27,506
AstraZeneca	21	$14,620
Boehringer Ingelheim	23	$11,987
Johnson & Johnson	7	$4,568
Sanofi-aventis U.S. LLC	2	$3,621
IBSA Pharma Inc.	9	$2,614
Clarus Therapeutics Inc.	2	$2,150
Sanofi US Services Inc.	1	$1,127
Tandem Diabetes Care, Inc.	4	$44
Amarin Pharma, Inc.	2	$38
Antares Pharma, Inc.	2	$37
Insulet Corporation	2	$35
Nevro Corp.	1	$34
Radius Health, Inc.	2	$26
Amgen	1	$20
Corcept Therapeutics	1	$14
Merck	1	$12

Kerem Ozer

Payments from drug & device makers

Who reported the general payments

How this compares

Other endocrinology, diabetes & metabolism in Round Rock